The underlying technology improves assay sensitivity; provides for detection of pathogens directly from clinical specimens such as blood, lung aspirates, urine, stool and swabs at low levels, without the need for time consuming and expensive techniques such as PCR; and can be utilized with all potential diagnostic targets, including nucleic acids and proteins.

The patent protects development of highly-sensitive immunoassay-based testing with expanded targets on the Great Basin testing platform.

"Great Basin is committed to protecting our intellectual assets and innovations, and providing distinctive diagnostic solutions to our customers," says Ryan Ashton, co-founder and Chief Executive Officer of Great Basin. "With this patent, directed to our proprietary compositions for diagnostic assays, we further protect our ability to deliver to customers the cost, ease-of-use and versatility they need in a molecular diagnostic system."

The amplification and detection compositions used by Great Basin, termed AMPED, enables the direct detection of pathogens present in clinical samples without requiring polymerase chain reaction-based (PCR) target amplification, a technology in molecular biology used to amplify DNA – and is now no longer limited to testing with only nucleic acids.

This patent further secures the intellectual property behind Great Basin’s advanced molecular diagnostics technology. Great Basin now has 5 issued patents in the U.S. and Europe.

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases.